Navigation Links
Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
Date:3/2/2012

The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don't rush are unharmed.

Data from a phase I clinical trial of patients with advanced pancreatic cancer and additional solid tumors recently published in the journal Clinical Cancer Research shows the strategy has promise. While the goal of any phase I trial is to establish the dosage that best balances effectiveness against side effects, 11 of the 19 patients treated achieved stable disease, which lasted for a median of 113 days.

"Really, the drug takes one of cancer's greatest strengths and turns it into a weakness," says Wells Messersmith, MD, co-leader of the Developmental Therapeutics Program at the University of Colorado Cancer Center and the clinical trial's national principal investigator.

Instead of going with the flow of the natural cell cycle, cancer cells amplify two signals PLK1 and PI3K which allows them to blast through the cell cycle and divide much more quickly. In the process, they break this step of the natural cell cycle, known as the G1 regulatory mechanism, and thus depend on the kick of PLK1 and P13K to push at a frenzied pace through replication.

It's specifically these two signals, PLK1 and PI3K, that rigosertib targets. With these signals turned off, cancer cells get stuck and die in the stage of the cell cycle called M phase while healthy cells that stuck to the slower, natural method of division chug past unharmed.

Wells Messersmith, MD, co-leader of the Developmental Therapeutics Program at the University of Colorado Cancer Center

"This one-two punch, targeting these two distinct signaling pathways, allows us to interfere twice with cancer cells' ability to replicate," Messersmith says. And it also allows doctors to target cancers that may have evolved resistance to one or the other target.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Extinct for 150 years, an iconic Galpagos giant tortoise species lives
2. Tortoise populations can withstand fires every 30 years
3. Giant tortoises show rewilding can work
4. In the race of life, better an adaptable tortoise than a fit hare
5. New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago
6. Madagascars radiated tortoise threatened with extinction
7. New theory shows that neither birth nor death stops a flock
8. Path to oxygen in Earths atmosphere: long series of starts and stops
9. Athletic girls more likely to have impaired bone structure if menstrual cycle stops
10. Policing stops cheaters from dominating groups of cooperative bacteria
11. Researchers find drug that stops progression of Parkinsons disease in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology: